Biosign Technologies Retains IR Firm Bay Street Connect and Grant of Stock Options

TORONTO, Nov. 14, 2011 /PRNewswire/ - Biosign Technologies Inc. (TSXV: BIO) (the "Company") is pleased to announce that it has retained Bay Street Connect to provide Biosign with financial communications and investor relations services for up to one year. The service contract with Bay Street Connect, a Toronto-based company that provides communications services to public Canadian companies, will focus on positioning Biosign with the investment community, market analysts and company stakeholders.

Additionally, the Company announced the grant of an aggregate of 750,000 stock options - 350,000 of such options were granted to a director and an officer of the Company, and 400,000 were granted to Bay Street Connect, pursuant to the Company's stock option plan.  The granted options expire in 5 years, have an exercise price of $0.385 per share and are subject to vesting.

About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, life style, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information, please visit: www.biosign.com.

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED